Biotechnology Use and Development Survey
Results
Results
All (57)
All (57) (30 to 40 of 57 results)
- Articles and reports: 88-001-X20030047882Description:
Biotechnology is an enabling technology - one that has been compared to electricity or microelectronics - because it has the potential to transform production processes, products and services in a wide range of sectors of the economy. At present, major applications of biotechnology are taking place in health, agrifood, and natural resources (e.g. forestry and mining). This survey is intended to quantify the level of industrial activity in biotechnology Research and Development by sector of application and to reveal trends in spending.
Release date: 2003-06-05 - 32. Features of Canadian Biotech Innovative Firms: Results from the Biotechnology Use and Development Survey - 2001 ArchivedArticles and reports: 88F0006X2003005Description:
The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2001 Biotechnology Use and Development Survey. Within the last few years, except for the amount of financing capital raised, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 358 in 1999 to 375 in 2001. The Human Health sector outpaces all the other sectors in terms of the number of firms, human resources, biotechnology revenues, biotechnology research and development expenditures, amount of financing capital raised, and the number of products in the pipeline. Contrary to medium-sized and large firms where the personnel is more homogenous, small firms employ mostly highly-qualified workers. The 2001 data show a maturing trend in small firms. Most firms could not hire enough people to fill all their vacancies (estimated at 953 positions in Canada) for the 2001 year.
Release date: 2003-03-28 - Articles and reports: 88F0006X2003003Description:
Results show that biotechnology companies in Canada are experiencing rapid growth and that Statistics Canada is now capturing more biotechnology activity. For example, between 1997 and 1999, Canadian biotechnology firms grew in number with core biotechnology firms increasing from 282 firms to 358. They brought in $1.9 billion in biotechnology revenues in 1999, compared with $813 million in 1997; they spent around $827 million on biotechnology research and development in 1999, compared with $494 million in 1997.
Release date: 2003-03-10 - Articles and reports: 88-003-X20030016474Geography: Canada, Province or territoryDescription:
In 2001, there were 375 biotechnology innovator firms in Canada, an increase of just under 5% from the 358 firms in 1999. Analysis beyond these overall statistics discloses a dynamic churning that is occurring among sectors, provinces and size groups.
Release date: 2003-02-18 - Articles and reports: 88-003-X20030016475Geography: CanadaDescription:
Data from the 2001 Biotechnology Use and Development Survey show that human resources in biotechnology increased substantially between 1999 and 2001. In this article, we attempt to answer two questions: What are the characteristics of the human resources engaged in the biotechnology field in Canada? Moreover, what are the main factors that contributed to the growth of these human resources in 2001?
Release date: 2003-02-18 - 36. Coming of age - biotech revenues are on the rise ArchivedArticles and reports: 88-003-X20030016476Geography: CanadaDescription:
Canadian biotechnology is gaining momentum. More firms are getting their products onto the markets and increasing revenues. With the human health sector leading the way, biotechnology revenues rose by a massive 343% for the 1997 to 2001 period, reaching $3.5 billion in 2001. During this same period, the number of firms increased by 33%.
Release date: 2003-02-18 - Articles and reports: 88F0006X2002003Description:
This is the final of three papers providing data and an overview of the results of the Biotechnology Use and Development Survey - 1999. Readers are encouraged to use the data. The next edition of the Biotechnology Use and Development Survey - 2001 is expected to be administered in the spring of 2002 with results available early in 2003.
Release date: 2002-03-28 - Articles and reports: 88F0006X2002004Description:
Spin-off firms made up over 34% of the core group of firms from the 1999 biotechnology survey. They also made up over 112 of the 270 small (under 50 employees) size firms, by far the largest group of core biotechnology, and half of the human health related firms, the largest sector of biotechnology firms. Central to this paper is the question: What are the general characteristics of this sub-group of core biotechnology firms?
Release date: 2002-03-28 - 39. We have learned a great deal! ArchivedArticles and reports: 88-003-X20020016146Geography: CanadaDescription:
This, the first issue of 2002 presents an opportunity to recapitulate some of the findings that we have reported during the life of the Bulletin. In an interview, Dr. Fred Gault, Director of Statistics Canada's Science, Innovation and Electronic Information Division, discusses some of the findings on innovation, e-commerce, emerging technologies, Internet use, the telecommunications industry, R&D and commercialization.
Release date: 2002-02-15 - Articles and reports: 88-003-X20020016149Geography: CanadaDescription:
According to the report Profile of Spin-off Firms in the Biotechnology Sector, three out of every 10 companies in Canada's rapidly expanding biotechnology sector in 1999 were spin-offs. These firms, which range from corporate spin-offs to biotechnology companies created by universities and research hospitals, accounted for more than one-quarter of total revenues in 1999.
Release date: 2002-02-15
Data (3)
Data (3) ((3 results))
- 1. Biotechnology use and development survey, indicators for innovative biotechnology firms by firm size ArchivedTable: 27-10-0266-01Frequency: Every 2 yearsDescription: Biotechnology use and development survey, indicators for innovative biotechnology firms by firms size for Canada, biennial survey from 1999 to 2005.Release date: 2008-09-26
- 2. Biotechnology use and development survey, indicators for innovative biotechnology firms by sector ArchivedTable: 27-10-0267-01Frequency: Every 2 yearsDescription: Biotechnology use and development survey, indicators for innovative biotechnology firms by sector, for Canada, biennial survey from 1999 to 2005.Release date: 2008-09-26
- 3. Biotechnology use and development survey, indicators for innovative biotechnology firms by region ArchivedTable: 27-10-0268-01Frequency: Every 2 yearsDescription: Biotechnology use and development survey, indicators for innovative biotechnology firms for Canada and by region , biennial survey from 1999 to 2005.Release date: 2008-09-26
Analysis (54)
Analysis (54) (0 to 10 of 54 results)
- Articles and reports: 88F0006X2007007Description: Results from the Survey of Innovation 2003 raised some interesting questions. First, an unexpected one-third of establishments in R&D services were not innovative. According to the guidelines of the Oslo Manual, innovative establishments are those that introduced a new or significantly improved product or process on to the market or into production, within a specified interval. Second, many of these non-innovative establishments indicated that satisfying existing customers was irrelevant to their firms success. This was very different response from all other types of firms.
This working paper provides a potential explanation of these unexpected results, as well as an overview of available information on establishments in R&D services (NAICS 5417) in the context of professional services generally. The paper assembles descriptive data to show that non-innovative establishments in R&D services differ significantly from other non-innovative establishments and, while not innovative, they are nevertheless highly inventive. It presents some evidence to suggest that they are venture firms (firms relying on infusions of investment capital rather than revenues from sales to sustain their operations) and proposes a specific set of indicators that would facilitate resolution of the nature of firms in this industry group.
Release date: 2007-12-20 - Articles and reports: 88F0006X2007006Description: This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.Release date: 2007-12-05
- 3. Results of the pilot survey on nanotechnologies ArchivedArticles and reports: 88-003-X200700210323Geography: CanadaDescription:
Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210324Geography: CanadaDescription:
Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210325Geography: CanadaDescription:
Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210326Geography: CanadaDescription:
Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.
Release date: 2007-10-09 - Articles and reports: 88F0006X2007005Description: This working paper provides results from a pilot survey on nanotechnology, which was appended to the Biotechnology Use and Development Survey 2005. The paper presents the conceptual issues and survey challenges relating to measurement of nanotechnology-related activities, as well as preliminary data on nanotechnology firms in Canada.Release date: 2007-08-31
- 8. Innovative biotech firms: Early results from the 2005 Biotechnology Use and Development Survey ArchivedArticles and reports: 88-003-X20070019620Geography: Canada, Province or territoryDescription:
Preliminary data from the Biotechnology Use and Development Survey (BUDS) 2005 indicate that growth continued in the sector, but at a slower pace than has been reported in earlier years. This article highlights some key biotechnology indicators for innovative biotech firms in Canada, by sector, size and province.
Release date: 2007-05-10 - Articles and reports: 88-003-X20060029246Geography: CanadaDescription:
While firms engaged in R&D services are part of the population of firms covered by the Research and Development in Canadian Industry (RDCI) survey and the Biotechnology Use and Development Survey (BUDS), this industry group is not covered by a typical industry survey. This means that there are no industry-specific figures for contribution to GDP or other typical measures of industrial activities and finances. However, data for the industry group are available from the Survey of Innovation 2003, along with other selected professional services. Data from that survey indicate that the establishments in R&D services in physical, engineering and life sciences may be part of a select and highly atypical group of firms and are discussed in this article.
Release date: 2006-06-27 - 10. Canadian biotechnology activity, 2003 ArchivedArticles and reports: 88-003-X20050028021Geography: CanadaDescription:
Between 1997 and 2003, the number of innovative biotechnology firms rose from 282 to 490. Biotechnology in Canada continued to expand between 2001 and 2003, generating revenues of almost $4 billion. Biotechnology companies have more than quadrupled their revenues since 1997, making biotechnology a fast growing activity.
Release date: 2005-06-20
- Previous Go to previous page of Analysis results
- 1 (current) Go to page 1 of Analysis results
- 2 Go to page 2 of Analysis results
- 3 Go to page 3 of Analysis results
- 4 Go to page 4 of Analysis results
- 5 Go to page 5 of Analysis results
- 6 Go to page 6 of Analysis results
- Next Go to next page of Analysis results
Reference (0)
Reference (0) (0 results)
No content available at this time.